Abstract
Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will
be treated with crizotinib administered orally. Crizotinib will be taken continuously until
disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each,
for a maximum of 12 cycles.
